- Home
- ADBE vs AZN Comparison
ADBE vs AZN Comparison
Compare ADBE & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADBE
- AZN
- Stock Information
- Founded
- ADBE 1982
- AZN 1992
- Country
- ADBE United States
- AZN United Kingdom
- Employees
- ADBE N/A
- AZN N/A
- Industry
- ADBE Computer Software: Prepackaged Software
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- ADBE Technology
- AZN Health Care
- Exchange
- ADBE Nasdaq
- AZN Nasdaq
- Market Cap
- ADBE 172.5B
- AZN 205.5B
- IPO Year
- ADBE 1986
- AZN 1993
- Fundamental
- Price
- ADBE $417.36
- AZN $72.83
- Analyst Decision
- ADBE Buy
- AZN Strong Buy
- Analyst Count
- ADBE 24
- AZN 5
- Target Price
- ADBE $515.09
- AZN $92.33
- AVG Volume (30 Days)
- ADBE 2.7M
- AZN 5.0M
- Earning Date
- ADBE 06-12-2025
- AZN 07-24-2025
- Dividend Yield
- ADBE N/A
- AZN 2.12%
- EPS Growth
- ADBE 44.73
- AZN 22.71
- EPS
- ADBE 15.16
- AZN 4.97
- Revenue
- ADBE $22,037,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- ADBE $11.17
- AZN $9.56
- Revenue Next Year
- ADBE $9.70
- AZN $6.09
- P/E Ratio
- ADBE $27.37
- AZN $28.82
- Revenue Growth
- ADBE 10.54
- AZN 15.48
- 52 Week Low
- ADBE $332.01
- AZN $61.24
- 52 Week High
- ADBE $587.75
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- ADBE 64.70
- AZN 61.90
- Support Level
- ADBE $410.47
- AZN $69.97
- Resistance Level
- ADBE $416.37
- AZN $71.41
- Average True Range (ATR)
- ADBE 5.50
- AZN 1.22
- MACD
- ADBE 0.35
- AZN 0.42
- Stochastic Oscillator
- ADBE 67.31
- AZN 94.74
About ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.